Aralez Pharmaceuticals, a global specialty pharmaceutical company, has announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled ‘compositions and methods for delivery of omeprazole plus acetylsalicylic acid’ that covers Yosprala (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omeprazole, in the US.
The USPTO issued US Patent number 9,539,214 on January 10, 2017, which will expire in late 2032 with possible patent term adjustment into early 2033. Aralez plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. Once listed there will be a total of four patents in the Orange Book for Yosprala.
Aralez Pharmaceuticals is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas.